Monoclonal antibody drugmaker United BioPharma Inc (聯合生技) yesterday said that its NT$1 billion (US$33.17 million) new plant in Hsinchu County would be able to produce 100kg of antibodies a year and satisfy the need for phase-three clinical trials and early market demand of a new drug.
The new plant will have two production lines, each with a 2,000-liter reactor, company executive director Shugene Lynn (林淑菁) said at an investors’ conference.
“We also reserved the space to build another 10 production lines for the new factory. With the extra lines, United Biopharma will be able to make 600kg of antibodies per year in the future and satisfy the demand of a new drug for the global market,” she added.
Construction is to begin by the end of this year and the factory is expected to be operational in 2016, Lynn said.
The company is developing three monoclonal antibody drug treatments and four monoclonal antibodies for use as biosimilars, company president Liao Mei-june (廖美君) said.
Among these antibodies, UB-421, which is used to treat AIDS, has completed phase-two clinical trials, while the company is to file an investigational new drug application for UB-621, which targets the Herpes simplex virus, by early next year, Liao said.
Other drugs made by the company are still in preclinical trials, she added.
United BioPharma plans to debut on the local Emerging Stock Market (興櫃市場) on Friday, with shares set at NT$85, the company said.
The debut is earlier than the time the company set in November last year.
The company will not release additional shares in its debut, said Victor Sun (孫潤本), the company’s special assistant to the chairperson.
The company’s capital is set at NT$1.15 billion, it said.
United Biomedical Inc Asia (聯亞生技), which manufactures and sells multiple medical products, owns 65 percent of United BioPharma’s shares, while Formosa Plastics Group (台塑集團), the nation’s largest industrial group, owns 25 percent, it added.
In the first half of this year, United Biopharma posted losses of NT$68.41 million, or NT$0.58 per share, because of R&D expenditures of NT$61.48 million, according to the company’s filing with the Taiwan Stock Exchange.
The company does not have comparable data for a year ago, as it was founded on Jan. 16.
Company chairperson Wang Chang-yi (王長怡) said United Biopharma plans to spend less than NT$200 million this year on R&D.
Although it has not yet reported revenue, the company expects to book licensing income next year, Wang said, without offering further information.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) would not produce its most advanced technologies in the US next year, Minister of Economic Affairs J.W. Kuo (郭智輝) said yesterday. Kuo made the comment during an appearance at the legislature, hours after the chipmaker announced that it would invest an additional US$100 billion to expand its manufacturing operations in the US. Asked by Taiwan People’s Party Legislator-at-large Chang Chi-kai (張啟楷) if TSMC would allow its most advanced technologies, the yet-to-be-released 2-nanometer and 1.6-nanometer processes, to go to the US in the near term, Kuo denied it. TSMC recently opened its first US factory, which produces 4-nanometer
GREAT SUCCESS: Republican Senator Todd Young expressed surprise at Trump’s comments and said he expects the administration to keep the program running US lawmakers who helped secure billions of dollars in subsidies for domestic semiconductor manufacturing rejected US President Donald Trump’s call to revoke the 2022 CHIPS and Science Act, signaling that any repeal effort in the US Congress would fall short. US Senate Minority Leader Chuck Schumer, who negotiated the law, on Wednesday said that Trump’s demand would fail, while a top Republican proponent, US Senator Todd Young, expressed surprise at the president’s comments and said he expects the administration to keep the program running. The CHIPS Act is “essential for America leading the world in tech, leading the world in AI [artificial
REACTIONS: While most analysts were positive about TSMC’s investment, one said the US expansion could disrupt the company’s supply-demand balance Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) new US$100 billion investment in the US would exert a positive effect on the chipmaker’s revenue in the medium term on the back of booming artificial intelligence (AI) chip demand from US chip designers, an International Data Corp (IDC) analyst said yesterday. “This is good for TSMC in terms of business expansion, as its major clients for advanced chips are US chip designers,” IDC senior semiconductor research manager Galen Zeng (曾冠瑋) said by telephone yesterday. “Besides, those US companies all consider supply chain resilience a business imperative,” Zeng said. That meant local supply would
Servers that might contain artificial intelligence (AI)-powering Nvidia Corp chips shipped from the US to Singapore ended up in Malaysia, but their actual final destination remains a mystery, Singaporean Minister for Home Affairs and Law K Shanmugam said yesterday. The US is cracking down on exports of advanced semiconductors to China, seeking to retain a competitive edge over the technology. However, Bloomberg News reported in late January that US officials were probing whether Chinese AI firm DeepSeek (深度求索) bought advanced Nvidia semiconductors through third parties in Singapore, skirting Washington’s restrictions. Shanmugam said the route of the chips emerged in the course of an
RSS